Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade

Background: Neuroendocrine neoplasms (NENs) are a rare group of tumors with a different clinical course, prognosis and location. Radioligand therapy (RLT) can be used as a first or second line of treatment. It is registered in gastroenteropancreatic NENs (GEP-NENs) as grades G1 and G2. Tumors with a...

Full description

Bibliographic Details
Published in:Pharmaceuticals
Main Authors: Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, Grzegorz Kamiński
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Subjects:
neuroendocrine neoplasms
NEN
RLT
PRRT
177-Lutetium
90-Yttrium
Online Access:https://www.mdpi.com/1424-8247/16/9/1205

Internet

https://www.mdpi.com/1424-8247/16/9/1205

Similar Items